 |
|
|
| |
L159F and V321A Sofosbuvir Treatment-Emergent HCV NS5B Substitutions
|
| |
| |
Reported by Jules Levin
AASLD 2014 Boston Nov 8-11
Evguenia S. Svarovskaia,1 Hadas Dvory-Sobol,1 Brian Doehle,1 Edward Gane,2 Ira M. Jacobson,3 David R. Nelson,4 Eric Lawitz,5 Diana M. Brainard,1 John G. McHutchison,1 Michael D. Miller,1 Hongmei Mo1
1Gilead Sciences, Inc., Foster City, CA; 2University of Auckland, Auckland, New Zealand; 3Weill Cornell Medical College, New York, NY; 4University of Florida, Gainesville, FL; 5Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX
|
| |
|
|
|
|
|
